Pimobendan is a medication sold chiefly as a veterinary product, with Vetmedin among its brand names. Pharmacologically it is a calcium sensitizer and a selective inhibitor of phosphodiesterase 3, and these actions give it positive inotropic effects, meaning it strengthens the heartbeat, together with vasodilator effects that widen blood vessels. Its main use is in the management of heart failure in dogs, most often when the failure is caused by myxomatous mitral valve disease, formerly called endocardiosis, or by dilated cardiomyopathy. Research cited in the source indicates that, given alone, pimobendan lengthens survival and improves quality of life in dogs with congestive heart failure secondary to mitral valve disease, compared with the ACE inhibitor benazepril. Under the brand name Acardi it is available for human use in Japan, and it is sold as a generic medication. This entry records what is held about the drug and is not medical or veterinary advice.
Facts
Mechanism of ActionNonsympathomimetic, nonglycoside positive inotropic action with vasodilation (inodilator) 3 Approved UseManagement of clinical signs of congestive heart failure 1 Significant RiskVentricular tachyarrhythmias may develop or worsen during treatment 3 Classification
Approval Status ATC ClassC: Cardiovascular System 2 Sources
1. FDA Grants Conditional Approval for the Use of Pimobendan to Delay Congestive Heart Failure in Dogs (KCVMA, 2022)
Body, approval background paragraph
Pimobendan has been approved to manage clinical signs of congestive heart failure
Body, approval status sentence
Pimobendan has been approved to manage clinical signs of congestive heart failure
View the Source2. WHO Collaborating Centre for Drug Statistics Methodology, ATC/DDD Index: the WHO ATCvet Index entries named Pimobendan
WHO Collaborating Centre for Drug Statistics Methodology, ATC/DDD IndexATCvet Index entry (veterinary code); ATC class derived from cited code QC01CE90 (main group C)Quote, ATCvet Index entry (veterinary code); ATC class derived from cited code QC01CE90 (main group C)
QC01CE90 pimobendan
View the Source 3. Pimobendan treatment in dogs with congestive heart failure (dvm360)
Pharmacology, classification sentence
is classified as an inodilator because of its nonsympathomimetic, nonglycoside positive inotropic
Pharmacology, mechanism sentence
is classified as an inodilator because of its nonsympathomimetic, nonglycoside positive inotropic
Adverse effects and precautions
ventricular tachyarrhythmias may develop or worsen while pimobendan is administered.
View the SourcePimobendan (Wikipedia)
Reader Challenges (0)
No disputes yet. Spotted an error or a better source? Open the first one.
Sign in to dispute this or suggest a correction.